Therapies for multiple sclerosis: translational achievements and outstanding needs. by Haghikia, A, Hohlfeld, R, Gold, R, Fugger, L

Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient by Wurm, H, Attfield, K, Iversen, AK, Gold, R, Fugger, L, Haghikia, A

Ageing & Sports by Müller P, 2, 3, Stiebler M, Schwarck S, 3, Haghikia A, 2, 4, Düzel E, 3, 4

Get full text

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy by Haghikia, A, Dendrou, C, Schneider, R, Grüter, T, Postert, T, Matzke, M, Stephanik, H, Fugger, L, Gold, R

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis by Gregory, A, Kaur, G, Punwani, D, Felce, J, Davis, S, Fugger, L, Dendrou, C, Attfield, K, Haghikia, A, Lambert, L, Leach, O, Prömel, S, Gold, R, Xifara, D, McVean, G, Butter, F, Mann, M, Poschmann, G, Nielsen, F, Siegel, R, Bell, J

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. by Gregory, A, Dendrou, C, Attfield, K, Haghikia, A, Xifara, D, Butter, F, Poschmann, G, Kaur, G, Lambert, L, Leach, O, Prömel, S, Punwani, D, Felce, J, Davis, S, Gold, R, Nielsen, F, Siegel, R, Mann, M, Bell, J, McVean, G, Fugger, L